+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      NF-κB inhibition delays DNA damage-induced senescence and aging in mice.

      The Journal of clinical investigation

      Transcriptional Activation, metabolism, genetics, Transcription Factor RelA, Signal Transduction, Protein Binding, pathology, drug therapy, Progeria, Phosphorylation, pharmacology, Peptides, Oxidative Stress, Mice, Transgenic, Mice, antagonists & inhibitors, I-kappa B Kinase, physiology, drug effects, Hepatocytes, Gene Expression Regulation, Endonucleases, DNA-Binding Proteins, DNA Damage, Cyclin-Dependent Kinase Inhibitor p16, Cells, Cultured, Cell Nucleus, Cell Aging, Animals, Aging

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The accumulation of cellular damage, including DNA damage, is thought to contribute to aging-related degenerative changes, but how damage drives aging is unknown. XFE progeroid syndrome is a disease of accelerated aging caused by a defect in DNA repair. NF-κB, a transcription factor activated by cellular damage and stress, has increased activity with aging and aging-related chronic diseases. To determine whether NF-κB drives aging in response to the accumulation of spontaneous, endogenous DNA damage, we measured the activation of NF-κB in WT and progeroid model mice. As both WT and progeroid mice aged, NF-κB was activated stochastically in a variety of cell types. Genetic depletion of one allele of the p65 subunit of NF-κB or treatment with a pharmacological inhibitor of the NF-κB-activating kinase, IKK, delayed the age-related symptoms and pathologies of progeroid mice. Additionally, inhibition of NF-κB reduced oxidative DNA damage and stress and delayed cellular senescence. These results indicate that the mechanism by which DNA damage drives aging is due in part to NF-κB activation. IKK/NF-κB inhibitors are sufficient to attenuate this damage and could provide clinical benefit for degenerative changes associated with accelerated aging disorders and normal aging.

          Related collections

          Author and article information



          Comment on this article